Shares of Allogene Therapeutics, Inc. (ALLO) are tanking over 40% on Friday morning after the U.S. Food and Drug Administration put a clinical hold on the clinical-stage biotech company's cancer drug trial.
ALLO is currently trading at $14.10, down $10.28 or 42.16%, on the Nasdaq, on a volume of 11.9 million shares, above average volume of 700 thousand shares. The stock has traded between $13.70 and $44.92 in the 52-week period.
Allogene Therapeutics announced that that following a report of a chromosomal abnormality in ALLO-501A CAR T cells in a patient treated in the ALPHA2 study, the FDA has placed a hold on the Company's AlloCAR T clinical trials.
The company said it will provide additional updates in the coming weeks following consultation with the FDA. The FDA continues to actively review the end of Phase 1 materials submitted in anticipation for an ALLO-501A pivotal Phase 2 trial.
For comments and feedback: editorial@rttnews.com